IXICO plc

("IXICO", the "Company" or the "Group")

IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform      

26 March 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it is aligning its IXI™ Platform with Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, to support clinical research.

The technology collaboration will create a unique neuroimaging data and analysis offering linking IXICO's IXI™ Platform with the Medidata Platform to deliver a differentiated, unified user experience for customers. This powerful combination will enable biopharma companies to conduct neuroimaging clinical trials with streamlined reporting of eligibility and safety criteria and to collect, upload, manage, and receive analysis on complex neuroimaging data within a highly secure, regulatory-compliant system.

The collaboration is expected to provide IXICO with expanded scale, opportunities for technological co-development, market reach, and an additional route to market beyond its existing commercial activities. The agreement is non-exclusive and IXICO will continue to contract directly with biopharma clients and seek other partnership opportunities outside of joint commercial activities with Medidata.

Bram Goorden, Chief Executive Officer of IXICO, commented: "This is an exciting opportunity to power the future of neuroimaging clinical trials. This commercial agreement supports our strategy to expand the reach of our platform and analytics capabilities and serve some of the most important clinical programs and biopharma customers at scale. Medidata is a highly respected global leader in life science solutions, and we are delighted to be working with them."

Wayne Walker, Senior Vice President, Data Experience at Medidata, commented: "Through this collaboration, both IXICO and Medidata can expand their impact in Central Nervous System clinical trials. Medidata's ability to deliver precise data for complex neurological conditions will elevate IXICO's proprietary platform, empowering CROs to deliver a vastly superior, unified experience to their biopharma sponsors and accelerating the critical clinical research needed to treat neurological disorders."

Ends

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.